Molecule News and Research

RSS

Nano-biosensors along with new imaging techniques can improve drug targeting in pancreatic cancer

UK and Australian scientists have been able to show ways in which we can markedly improve drug targeting of solid tumours, using tiny 'biosensors' along with new advanced imaging techniques.

12 Jun 2013

Celgene announces positive results from first phase III study of apremilast in psoriatic arthritis

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced 52-week results from PALACE 1, the Company's first phase III study in psoriatic arthritis at the European Congress of Rheumatology annual meeting in Madrid, Spain.

12 Jun 2013

Tumor suppressor p53 inactivation and restoration: an interview with Dr. Xin Lu, Ludwig Institute for Cancer Research

Before we talk about p53, it is important to understand why cancer cells are a problem for the body. Cancer cells multiply recklessly, refuse to die and blithely metastasize to set up shop in places where they don’t belong.

12 Jun 2013

Hebrew University student develops drug formulations to treat illnesses through skin applications

New, more efficient drug formulations designed to treat illnesses through skin applications -- thus avoiding serious side effects associated with oral drug-taking -- have been developed by a student at the Hebrew University of Jerusalem.

12 Jun 2013

PSMA enzyme could become hallmark of new generation of biomarkers for prostate cancer treatment

No matter where they have hidden, metastatic prostate cancer cells still express some of the same signaling as normal prostate cells; in some cases even more so, as with the PSMA enzyme. Harnessing this enzyme could mean the beginning of a new platform for prostate cancer detection, staging, treatment and post-treatment monitoring, say researchers at the Society of Nuclear Medicine and Molecular Imaging's 2013 Annual Meeting.

12 Jun 2013

Research could lead to new ways to combat chlamydia

A protein secreted by the chlamydia bug has a very unusual structure, according to scientists in the School of Medicine at The University of Texas Health Science Center San Antonio. The discovery of the protein's shape could lead to novel strategies for diagnosing and treating chlamydia, a sexually transmitted disease that infects an estimated 2.8 million people in the U.S. each year.

12 Jun 2013

Sensational proteomics results enabled by Bruker’s new IMPACT HD™ Mass Spectrometer with Novel CaptiveSpray™ nanoBooster Ion Source

At the 61st ASMS conference, Bruker introduces exciting new High-Definition capabilities in proteomics and biomarker research. Patented low-noise Captivespray nanoBooster™ ionization coupled with record high-speed digitization Qq-TOF technology and steered by intelligent acquisition software defines complex samples more sharply than ever before.

10 Jun 2013

Powerful new mass spectrometry systems and solutions for life-science research, clinical research, pharma and applied markets announced by Bruker

At the 61st ASMS Conference on Mass Spectrometry and Allied Topics, Bruker today announced mass spectrometry-based product introductions for life-science and clinical research, for biotech/pharma/CRO customers, as well as for industrial and applied markets. The new mass spectrometry systems and solutions are designed to deliver confident analyses with dramatically enhanced resolution, sensitivity and precision.

10 Jun 2013

New LC-MS software to transform high performance mass spectrometry unveiled by Thermo Fisher Scientific

Thermo Fisher Scientific Inc., the world leader in serving science, today introduced 10 new or updated software packages to help customers harness the power of its new-generation liquid chromatography-mass spectrometry (LC-MS) instruments and turn data into knowledge in a wide range of discovery and quantitation experiments.

From Thermo Fisher Scientific Inc. 10 Jun 2013

World’s first “Tribrid” LC-MS launched by Thermo Fisher Scientific

Thermo Fisher Scientific Inc., the world leader in serving science, introduced the Thermo Scientific Orbitrap Fusion Tribrid liquid chromatography-mass spectrometry (LC-MS) system, combining its three mass analyzers –quadrupole, Orbitrap and linear ion trap – in a novel “Tribrid” architecture that offers unprecedented depth of analysis of complex biological samples.

From Thermo Fisher Scientific Inc. 10 Jun 2013

SUNY Downstate to receive grant to advance blood test to predict breast cancer progression

SUNY Downstate Medical Center will receive up to $50,000 from the statewide SUNY Technology Accelerator Fund to advance a blood test to determine breast cancer prognosis.

10 Jun 2013

Cedars-Sinai opens Phase III clinical trial for patients with intestinal carcinoid cancer

Working to improve treatment and survivorship outcomes, the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute has opened a Phase III clinical trial of targeted radiation for patients with intestinal carcinoid cancer that has spread beyond the intestine.

10 Jun 2013

Researchers mobilize brain's native stem cells to replenish neuron lost in Huntington's disease

Researchers have been able to mobilize the brain's native stem cells to replenish a type of neuron lost in Huntington's disease.

7 Jun 2013

Available drugs may have a dramatic impact on children stricken with Tay-Sachs disease

A team of researchers has made a significant discovery which may have a dramatic impact on children stricken with Tay-Sachs disease, a degenerative and fatal neurological condition that often strikes in the early months of life.

7 Jun 2013

Inflection Biosciences signs license agreement with CNIO to develop kinase inhibitors for cancer treatment

Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced that it has entered into a license agreement with the Spanish National Cancer Research Centre (CNIO) for the exclusive, worldwide rights to develop and commercialise several novel kinase inhibitors for the treatment of cancer.

6 Jun 2013

Researchers provide insights into potential therapeutic approaches to Down syndrome

University of Michigan researchers have determined how a gene that is known to be defective in Down syndrome is regulated and how its dysregulation may lead to neurological defects, providing insights into potential therapeutic approaches to an aspect of the syndrome.

6 Jun 2013

BioTools bridges the empirical: computational chemistry chasm with ComputeVOA

Chiral molecules, those “left/right” mirror image marvels of nature, determine much of our biology and, as a result, are of prime interest to biologists, organic chemists, and especially, the pharmaceutical industry.

4 Jun 2013

Researchers demonstrate how modified citrus pectin works against cancer

A new review by researchers at the University of Maryland School of Medicine highlights a large body of published research demonstrating how modified citrus pectin, works against cancer.

4 Jun 2013

New technique selectively represses unwanted immune reactions without disabling immune system

The human immune system is remarkably efficient, but sometimes its attack is misdirected, leading to allergies, autoimmune diseases and rejection of transplant organs and therapeutic drugs. Current immune suppressants have major drawbacks, but a team from The Scripps Research Institute (TSRI) has demonstrated a new technique that may lead to a better way to selectively repress unwanted immune reactions without disabling the immune system as a whole.

4 Jun 2013

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.

4 Jun 2013

Molecule News and Research

Nano-biosensors along with new imaging techniques can improve drug targeting in pancreatic cancer

Celgene announces positive results from first phase III study of apremilast in psoriatic arthritis

Tumor suppressor p53 inactivation and restoration: an interview with Dr. Xin Lu, Ludwig Institute for Cancer Research

Hebrew University student develops drug formulations to treat illnesses through skin applications

PSMA enzyme could become hallmark of new generation of biomarkers for prostate cancer treatment

Research could lead to new ways to combat chlamydia

Sensational proteomics results enabled by Bruker’s new IMPACT HD™ Mass Spectrometer with Novel CaptiveSpray™ nanoBooster Ion Source

Powerful new mass spectrometry systems and solutions for life-science research, clinical research, pharma and applied markets announced by Bruker

New LC-MS software to transform high performance mass spectrometry unveiled by Thermo Fisher Scientific

World’s first “Tribrid” LC-MS launched by Thermo Fisher Scientific

SUNY Downstate to receive grant to advance blood test to predict breast cancer progression

Cedars-Sinai opens Phase III clinical trial for patients with intestinal carcinoid cancer

Researchers mobilize brain's native stem cells to replenish neuron lost in Huntington's disease

Available drugs may have a dramatic impact on children stricken with Tay-Sachs disease

Inflection Biosciences signs license agreement with CNIO to develop kinase inhibitors for cancer treatment

Researchers provide insights into potential therapeutic approaches to Down syndrome

BioTools bridges the empirical: computational chemistry chasm with ComputeVOA

Researchers demonstrate how modified citrus pectin works against cancer

New technique selectively represses unwanted immune reactions without disabling immune system

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News